Sector comment Korea / Pharmaceutical/Biotech 11 February 2016 OVERWEIGHT Event Stocks under coverage Company Rating Price Target price ( 주 : 2 월 5 일종가기준 ) Impact Action and recommendation 박재철, Analyst 3774 7165 jaechul.park@miraeasset.com See the last page of this report for important disclosures
2 2
3 3
4 4
5 5
6 6
Global Korea India/ Russia Japan China Reference Product Avastin Enbrel Herceptin Humira Lantus MabThera/Rituxan Remicade INN bevacizumab etanercept trastuzumab adalimumab insulin glargine rituximab infliximab Indication Cancer Autoimmune disease HER2+ breast cancer Autoimmune disease Diabetes CD20+ B cell MM, RA Autoimmune disease Originator Roche Pfizer/Amgen Roche Abbvie Sanofi Roche J&J/Merck Patent Expiry (US) Jul. 2019 Aug. 2019 Jun. 2019 Dec. 2016 Feb. 2015 2018 Onwards Sep. 2018 Patent Expiry Jan. 2022 Aug. 2015 Aug. 2015 Apr. 2018 May. 2015 2014/15 Onwards Feb. 2015 Sales (2014, USD m) 7,018 8,915 6,863 12,543 8,428 7,546 9,885 Sales (2019E, USD m) 6,711 7,766 5,402 16,662 3,965 5,516 6,633 Amgen/Allergan ABP 215 ABP 980 ABP 501 ABP 798 ABP 710 (EU/Asia/LatAm) (US/EU/AU/CA) (AU) Boehringer Ingelheim BI 695502 BI 695501 Basaglar BI695500-halted (US/EU/Asia/LatAm w/lilly (US/EU/LatAm) Pfizer PF-06439535 PF-05280014 PF-06410293 PF-05280586 PF-06438179 (US/EU/KR/AU/RU) (US/EU/JP/KR) Sandoz (Novartis) GP2015 GP2017 GP2013 Coherus CHS-0214 CHS-1402 Unknown (US/EU/JP) (US) Celltrion CT-P16 CT-P05 Herzuma(CT-P06) CT-P17 Truxima(CT-P10) Remsima(CT-P13), US/EU-P3 (US/EU/LatAm) (US-pre/EU/JP/KR) Samsung Bioepsis/ Biogen/Merck SB8 Benepali/Brenzys (SB4)-EU/KR SB3 (EU/KR/India) SB5 SB9 Renflexis(SB2) (EUKR-approved) Dong-A/Meiji Seika DMB3111 (KR/JP) LG Life Science LBEC0101 LBAL LBRx LBIM-0101 (JP/KR) (JP/KR) Aprogen/Binex AP052 NI071/GS071 Nichi-Iko/Schnell (KR/JP) Biocad BCD-021 BCD-022 BCD-057 BCD-020 (EU/India) (Russia/Ukraine) (Russia) (EU/India/LatAm) Biocon/Mylan MYL-1420O Unknown Bmab-200 BMO2 Basalog EU-Phase1 (US/India) Dr. Reddys Reditux Epirus BOW 030 BOW 050 BOW 015 (US) (US) Intas Intacept Mabtas Biopharmaceuticals Reliance Life Sciences R-TPR-023 R-TPR-016 R-TPR-021 R-TPR-017 Unknown Fujifilm Kyowa/ Unknown FKB-327 AstraZeneca (JP) (US/UK) Nichi-Iko NI-071 (JP) Hisun-Pfizer AnBaiNuo (CN) Genor Biopharma GB222 GB221 GB232 GB242 (Walvax Biotech) (CN) (CN/Global) (CN/Global) (CN) Shanghai CP Reumatocept CMAB302 Guojian/Cipla (CN/India/LatAm) (CN) Discovery Preclinical IND Phase I Phase II Phase III BLA Submission Approval 7 7
Recommendations 종목별투자의견 (12 개월기준 ) BUY : 현주가대비목표주가 +10% 초과 HOLD : 현주가대비목표주가 ±10% 이내 REDUCE : 현주가대비목표주가 -10% 초과단, 업종투자의견에의한 ±10% 내의조정치감안가능 Compliance Notice 업종별투자의견 OVERWEIGHT : 현업종지수대비 +10% 초과 NEUTRAL : 현업종지수대비 ±10% 이내 UNDERWEIGHT : 현업종지수대비 -10% 초과 Distribution of Ratings 조사분석자료투자등급비율 ( 기준일 : 20160129) BUY ( 매수 ) : 85.9% HOLD ( 중립 / 보유 ) : 12.9% REDUCE ( 매도 ) : 1.2% 합계 : 100% 동자료의금융투자분석사와배우자는자료작성일현재동자료상에언급된기업들의금융투자상품및권리를보유하고있지않습니다. 당사는자료작성일현재동자료상에언급된기업들의주식을기초자산으로하는 ELW 의발행회사및유동성공급자가아닙니다. 본자료는투자자의증권투자를돕기위하여당사고객에한하여배포되는자료로서어떠한경우에도복사되거나대여될수없습니다. 본조사자료에수록된내용은당사리서치센터가신뢰할만한자료및정보로부터얻어진것이나당사는그정확성이나완전성을보장할수없습니다. 따라서, 어떠한경우에도본자료는고객의증권투자의결과에대한법적책임소재에대한증빙자료로사용될수없습니다. 동자료는기관투자가또는제 3 자에게사전제공한사실이없습니다. 자료에게재된내용들은본인의의견을정확하게반영하고있으며, 외부의부당한압력이나간섭없이작성되었음을확인합니다. [ 작성자 : 박재철 ] 8 8